Category Archives: Dual/triple agonist

Dexcom Q2 ’26 Earnings; Novo Ziltivekimab CVOT Miss; CSPC Initiates China-Based QM Dual Agonist Study

Three cardiometabolic-related news items have been observed: Dexcom hosted its Q2 ’26 earnings call (view press release; view slides); Novo’s Ph3 ZEUS trial evaluating ziltivekimab missed the primary CV endpoint (view press release); and CSPC initiated a Ph1 study evaluating its QM GLP-1/GIP dual agonist (view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Viking, Madrigal, Sanofi, Alnylam, Regeneron Q2 ’26 Earnings; Lilly Invests in KwikPen US Manufacturing Site; Verdiva Doses First Patient in Ph1 VRB-103 Study

A series of cardiometabolic-related news items has been observed from Viking Therapeutics, Madrigal Pharmaceuticals, Sanofi, Alnylam, Regeneron, Resilience/Lilly, and Verdiva Bio. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Altimmune Topline Ph2 Pemvidutide AUD Data; GSK Q2 ’26 Earnings; New Pfizer Ph1 Oral GLP-1RA Study; Antag Ph2a GIP Antagonist Study; Salubris Ph2 Lp(a) Study

A series of cardiometabolic-related news items has been observed from Altimmune, GSK, Pfizer, Antag Therapeutics, and Shenzhen Salubris Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

AZ Q2 ’26 Earnings; Ex-Dexcom Executive Joins Luna Diabetes; Ascletis Preclinical Tri-Agonist Data; Ionis Pediatric Olezarsen Study; Lexicon Ph3 Sota Study; Veru Ph2b Enobosarm Study

A series of cardiometabolic-related news items has been observed from AstraZeneca, Luna Diabetes, Ascletis Pharma, Ionis Pharmaceuticals, Lexicon Pharmaceuticals, and Veru. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Verdiva Appoints Ex-Metsera Execs; Zealand Initiates New GIP Ph1 Obesity Study; MannKind Furoscix ReadyFlow US Approval; July CHMP Highlights; Evogene Partners for PCSK9i Development

A series of cardiometabolic-related news items has been observed from Verdiva Bio, Zealand Pharma, MannKind, FDA, EMA, and Evogene/ELEO. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Roche Q2 ’26 Earnings; New Retatrutide Ph3 Data; Trinity Biotech Partners with Latch Medical; Dexcom Joins FDA TEMPO Pilot Program

A series of cardiometabolic-related news items has been observed from Roche, Lilly, Trinity Biotech, and Dexcom. Below, FENIX provides highlights and insights for the respective news items, including insight into Lilly’s retatrutide regulatory strategy.

This content is for Read Less members only.

Already a member? Log in here

Arrowhead Reports Positive Ph3 Plozasiran Data; Avaí Partners for Insulin-Producing Cells; Novo Posts AMAZE 9 Zenagamtide Study; MiniMed Flex System Covered by Medicare

A series of cardiometabolic-related news items has been observed from Arrowhead Pharmaceuticals, Avaí Bio, Novo Nordisk, and MiniMed. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Icosema Launches in China; Medicare GLP-1 Bridge Reaches 100k Patients; Ex-Lilly Exec Joins Zealand; July CHMP Agenda

A series of cardiometabolic-related news items has been observed by Fangzhou/Novo Nordisk, CMS, Zealand Pharma, and EMA. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Merck’s Oral PCSK9i Approved by FDA; BI Ph2 Triple Agonist Study; Abbott Q2 ’26 Earnings; Syntis Ph1 Obesity Data; Lilly Invests in Oura; Braveheart IPO

A series of cardiometabolic-related news items has been observed from Merck, Boehringer Ingelheim, Abbott, Syntis Bio, Oura/Lilly, and Braveheart. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Novo’s Wegovy Pill Receives Approval in EU; Gubra Initiates FIH Study for Muscle-Sparing Asset; GSK Initiates Ph3 Efimosfermin Studies in MASH; Fractyl One Year Data; Ascletis Selects Another FDC in Obesity; Rani Topline Ph1 Data; BI H1 2026 Updates

A series of cardiometabolic-related news items has been observed from Novo Nordisk, Gubra, GSK, Fractyl Health, Ascletis Pharma, Rani Therapeutics, and Boehringer Ingelheim. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here